Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly intravenous GLM101 in participants with PMM2-CDG
2024-520109-37-00Phase 2Authorised
- Sponsor
- Glycomine
- Start
- Jul 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG) comparing GLM101 initial treatment arm with Placebo then GLM101 delayed-start arm (2 arms). Primary endpoint: Primary: Change from baseline in ICARS at 24 weeks. Planned start Jul 2025; status: authorised.
02
Drugs
GLM101
03
Conditions
phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG)
Beyond the preview
Go deeper on 2024-520109-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520109-37-00.